Drugs / Pegylated Interferon α2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03090035 | Jan → Jul 2014 | chronic hepatitis C virus infection | Sheikh Zayed Medical College | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Interferon α2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03090035 ↗ |
| Known as | pegIFN | “In all patients Pegulated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses.” NCT03090035 ↗ |